Physician profile
Brandy Morris
NPI 1043934490
$2,519.57
in general payments reported to CMS, 2019-2025
16 companies · $410 in 2025
The $410 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $521 · 2024: $1,589 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,354 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,354.09 |
| Education | $165.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $986.22 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $289.74 | 2023-2024 | Austedo Xr, Austedo |
| E.R. Squibb & Sons, L.L.C. | $195.02 | 2024 | Zeposia |
| Genentech USA, INC. | $184.63 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Genzyme Corporation | $136.29 | 2023 | |
| Alexion Pharmaceuticals, INC. | $127.52 | 2024-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $109.72 | 2024-2025 | |
| Sk Life Science, INC. | $103.55 | 2023-2024 | Xcopri |
| Lundbeck LLC | $92.62 | 2023-2024 | Vyepti, Rexulti |
| Janssen Biotech, INC. | $77.99 | 2025 | Tremfya |
| Lilly USA, LLC | $63.78 | 2024 | Kisunla, Amyvid, Reyvow |
| Pfizer INC. | $47.68 | 2024-2025 | |
| Celgene Corporation | $34.64 | 2024-2025 | Zeposia |
| Argenx US, INC. | $32.07 | 2024 | Vyvgart Hytrulo |
| Otsuka America Pharmaceutical, INC. | $21.14 | 2025 | Rexulti |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $16.96 | 2025 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.